Traders should now look for long-biased trades in MTG as long as it's trending above its 50-day at $2.76 or above its recent low of $2.36, and then once it sustains a move or close above those breakout levels with volume that hits near or above 4.90 million shares. If that breakout triggers soon, then MTG will set up to re-test or possibly take out its next major overhead resistance levels at $4 to $5.

Five Star Quality

Five Star Quality ( FVE) operates senior living communities, including independent living or congregate care communities, assisted living communities and skilled nursing facilities. This stock closed up 4.4% to $6.34 on Thursday.

Thursday's Range: $6.08-$6.40

52-Week Range: $2.98-$6.49

Volume: 412,000

Three-Month Average Volume: 343,548

From a technical perspective, FVE trended higher here right above some near-term support at $6 with above-average volume. This stock has been uptrending strong for the last three months, with shares soaring higher from its low of $4.45 to its recent high of $6.49. During that move, shares of FVE have been mostly making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of FVE within range of triggering a major breakout trade. That trade will hit if FVE manages to take out its 52-week high of $6.49 with high volume.

Traders should now look for long-biased trades in FVE as long as it's trending above some near-term support levels $6 to $5.91 or its 50-day at $5.62, and then once it sustains a move or close above its 52-week high of $6.49 with volume that hits near or above 343,548 shares. If that breakout triggers soon, then FVE will set up to re-test or possibly take out its next major overhead resistance levels at $7.50 to $8. Any high-volume move above $8 will then put $8.50 to $8.95 into range for shares of FVE.

Smart Technologies

Smart Technologies ( SMT) designs, develops and sells interactive technology products. This stock closed up 7.1% to $1.50 in recent trading.

Thursday's Range: $1.44-$1.60

52-Week Range: $1.10-$3.43

If you liked this article you might like

Goodbye CytRx, Your Game Is Over

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle